Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 9, 2026, 5:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 115 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Endo USA Inc., a Keenova Therapeutics Company Clear all
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Investigation of Surgery, Collagenase, and Restorex for the Improvement of Peyronie's

NCT04786106
View directory record Official record
Conditions
Peyronie's Disease
Interventions
Collagenase Clostridium Histolyticum 0.9 MG [Xiaflex] (CCH), Penile Plication Surgery, Incision and Grafting (I&G) Surgery, RestoreX Penile Traction Device
Drug · Procedure · Device
Lead sponsor
Charitable Union for the Research and Education of Peyronie's Disease
Other
Eligibility
18 Years and older · Male only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2027
U.S. locations
1
States / cities
Orem, Utah
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 9, 2026, 5:59 AM EDT
Terminated No phase listed Observational

Long-term Follow-up Durability (Efficacy) Study of EN3835 for the Treatment of AC of the Shoulder (Frozen Shoulder)

NCT04680156
View directory record Official record
Conditions
Adhesive Capsulitis, Frozen Shoulder
Interventions
Previously treated with EN3835 up to 1.74 mg or Placebo in EN3835-210 or the pivotal phase 3 studies
Drug
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
30
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 25 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2022 · Synced Oct 9, 2026, 5:59 AM EDT
Completed No phase listed Observational

The Evolution and Management of Migraine Recurrence Beyond 24 Hours

NCT00754611
View directory record Official record
Conditions
Migraine
Interventions
Not listed
Lead sponsor
Rowan University
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Stratford, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 28, 2019 · Synced Oct 9, 2026, 5:59 AM EDT
Terminated No phase listed Observational

Real-World Data Study to Understand Participant Treatment Outcomes for Dupuytren's Contracture

NCT05877066
View directory record Official record
Conditions
Dupuytren's Contracture
Interventions
Not listed
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
7
States / cities
Phoenix, Arizona • Greenwich, Connecticut • Temple Terrace, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2024 · Synced Oct 9, 2026, 5:59 AM EDT
Completed Phase 3 Interventional Results available

Time to Eugonadal Range, Time to Steady State and Drying Time

NCT01228071
View directory record Official record
Conditions
Male Hypogonadism
Interventions
testosterone gel 2%
Drug
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
8
States / cities
Tucson, Arizona • Middlebury, Connecticut • Oviedo, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2017 · Synced Oct 9, 2026, 5:59 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Impact of CCH Treatment of Buttock and Thigh Cellulite in Adult Women

NCT04209530
View directory record Official record
Conditions
Cellulite, Edematous Fibrosclerotic Panniculopathy (EFP)
Interventions
EN3835
Drug
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Coral Gables, Florida
Source: ClinicalTrials.gov public record
Updated Oct 7, 2021 · Synced Oct 9, 2026, 5:59 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Effectiveness and Safety of EN3835 in the Treatment of Cellulite in Women

NCT03446781
View directory record Official record
Conditions
Edematous Fibrosclerotic Panniculopathy (Cellulite)
Interventions
EN3835, Placebo
Biological
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
422 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
25
States / cities
Glendale, Arizona • North Little Rock, Arkansas • Beverly Hills, California + 22 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Oct 9, 2026, 5:59 AM EDT
Terminated Phase 3 Interventional

EN3285 for the Prevention or Delay of Oral Mucositis in Patients With Head and Neck Cancer

NCT00574860
View directory record Official record
Conditions
Oral Mucositis, Head and Neck Cancer
Interventions
EN3285, Placebo, Standard of care
Drug · Other
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
2
States / cities
Louisville, Kentucky • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 20, 2013 · Synced Oct 9, 2026, 5:59 AM EDT
Completed Phase 3 Interventional Results available

Administration of Two Injections for Multiple Dupuytren's Contractures

NCT01407068
View directory record Official record
Conditions
Dupuytren's Contracture
Interventions
AA4500 collagenase clostridium histolyticum
Biological
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
4
States / cities
Tucson, Arizona • Indianapolis, Indiana • Stony Brook, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2017 · Synced Oct 9, 2026, 5:59 AM EDT
Completed Phase 4 Interventional

Pilot Study of the Efficacy and Safety of Lidoderm Patch in the Treatment of Low Back Pain

NCT00904475
View directory record Official record
Conditions
Chronic Low Back Pain
Interventions
Lidoderm®
Drug
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
6
States / cities
Birmingham, Alabama • Hueytown, Alabama • Phoenix, Arizona + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2010 · Synced Oct 9, 2026, 5:59 AM EDT
Completed Phase 2 Interventional Results available

Pharmacokinetics of a Single Treatment Cycle of AA4500 0.58 mg in Men With Peyronie's Disease

NCT01430169
View directory record Official record
Conditions
Peyronie's Disease
Interventions
AA4500
Biological
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Burbank, California
Source: ClinicalTrials.gov public record
Updated Oct 5, 2017 · Synced Oct 9, 2026, 5:59 AM EDT
Completed Phase 3 Interventional Results available

Long-Term Study of EN3835 (CCH-aaes) in Edematous Fibrosclerotic Panniculopathy (Cellulite)

NCT03526549
View directory record Official record
Conditions
Edematous Fibrosclerotic Panniculopathy, Cellulite
Interventions
CCH-aaes, Observation
Biological · Other
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
483 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
42
States / cities
Glendale, Arizona • Scottsdale, Arizona • North Little Rock, Arkansas + 33 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2023 · Synced Oct 9, 2026, 5:59 AM EDT
Completed Phase 4 Interventional

Topical Lidocaine Patch in Low Back Pain

NCT00904540
View directory record Official record
Conditions
Acute and Chronic Non-radicular LBP
Interventions
Lidoderm®
Drug
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
7
States / cities
Phoenix, Arizona • Mill Valley, California • Weston, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 2, 2024 · Synced Oct 9, 2026, 5:59 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Evaluate the Depth and Duration of Anesthesia

NCT00891163
View directory record Official record
Conditions
Pain
Interventions
Synera™ Topical Patch (70 mg lidocaine/70 mg tetracaine), Placebo Patch
Drug
Lead sponsor
ZARS Pharma Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated May 1, 2009 · Synced Oct 9, 2026, 5:59 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Prevention of Menstrual Migraines: Using Frovatriptan or Placebo During Hormone Free Intervals

NCT00700128
View directory record Official record
Conditions
Migraines, Bleeding, Spotting
Interventions
frovatriptan, placebo
Drug
Lead sponsor
Scott and White Hospital & Clinic
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Temple, Texas
Source: ClinicalTrials.gov public record
Updated Jul 25, 2011 · Synced Oct 9, 2026, 5:59 AM EDT
Terminated Phase 4 Interventional Results available

Lumbar Stenosis Outcomes Research II

NCT00652093
View directory record Official record
Conditions
Lumbar Spinal Stenosis
Interventions
opana then darvocet then placebo, opana then placebo then darvocet, placebo then opana then darvocet, Placebo then darvocet then opana, Darvocet then opana then placebo, Darvocet then placebo then opana
Drug
Lead sponsor
University of Rochester
Other
Eligibility
50 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Mar 25, 2016 · Synced Oct 9, 2026, 5:59 AM EDT
Completed No phase listed Observational

Longterm Observational Study in Subjects Treated With AA4500 in AUX-CC-854, 856, 857, 858 & 859

NCT00954746
View directory record Official record
Conditions
Dupuytren's Disease
Interventions
Not listed
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older
Enrollment
645 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
23
States / cities
Phoenix, Arizona • Tucson, Arizona • Burbank, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2015 · Synced Oct 9, 2026, 5:59 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of the Lidoderm Patch Applied to Patients With Osteoarthritis of the Knee

NCT00589979
View directory record Official record
Conditions
Osteoarthritis of the Knee
Interventions
Lidoderm (Lidocaine 5% Patch), Placebo Patch
Drug
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
37 Years and older
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
20
States / cities
Paradise Valley, Arizona • Phoenix, Arizona • Milford, Connecticut + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2017 · Synced Oct 9, 2026, 5:59 AM EDT
Active, not recruiting Phase 4 Interventional

Safety and Efficacy of Collagenase Clostridium Histolyticum After Prior Intralesional PRP for Peyronie's Disease

NCT05777031
View directory record Official record
Conditions
Peyronie Disease, Sexual Dysfunctions, Psychological, Genital Diseases, Male
Interventions
Collagenase Clostridium Histolyticum (CCH)
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 75 Years · Male only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 9, 2026, 5:59 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Oxymorphone Extended Release in Opioid-Experienced Patients With Chronic Non-Malignant Pain

NCT00226421
View directory record Official record
Conditions
Chronic Pain
Interventions
Oxymorphone Extended Release
Drug
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
31
States / cities
Hueytown, Alabama • Phoenix, Arizona • Colorado Springs, Colorado + 26 more
Source: ClinicalTrials.gov public record
Updated Jan 2, 2024 · Synced Oct 9, 2026, 5:59 AM EDT
Completed Phase 3 Interventional Results available

A Study of AA4500 in Men With Peyronie's Disease

NCT01243411
View directory record Official record
Conditions
Peyronie's Disease
Interventions
AA4500
Biological
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older · Male only
Enrollment
348 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
13
States / cities
Burbank, California • Middlebury, Connecticut • New Haven, Connecticut + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2017 · Synced Oct 9, 2026, 5:59 AM EDT
Completed Phase 4 Interventional

A Study Of Lidocaine Patch 5% Alone, Gabapentin Alone, And Lidocaine Patch 5% And Gabapentin In Combination For The Relief Of Pain In Patients With Diverse Peripheral Neuropathic Pain Conditions

NCT00904202
View directory record Official record
Conditions
Postherpetic Neuralgia, Diabetic Neuropathy, Complex Regional Pain Syndrome, Carpal Tunnel Syndrome, HIV Neuropathy, Idiopathic Sensory Neuropathy, Peripheral Neuropathy
Interventions
Placebo Capsules + Placebo Patch, Placebo capsules + Lidoderm®, Gabapentin + Placebo, Gabapentin + Lidoderm®, Gabapentin 300 mg capsules 1800 mg/day + placebo patch, Gabapentin 1800 mg/day + Lidoderm patch
Drug
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
7
States / cities
Birmingham, Alabama • Hueytown, Alabama • Phoenix, Arizona + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 2, 2024 · Synced Oct 9, 2026, 5:59 AM EDT
Completed Phase 1 Interventional Results available

A Pharmacokinetic Study of AA4500 (XIAFLEX™, Proposed Name) in Subjects With Dupuytren's Contracture

NCT00528931
View directory record Official record
Conditions
Dupuytren's Contracture
Interventions
collagenase clostridium histolyticum
Biological
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Burbank, California
Source: ClinicalTrials.gov public record
Updated Oct 5, 2017 · Synced Oct 9, 2026, 5:59 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Injection Techniques of Collagenase Clostridium Histolyticum (CCH) for the Treatment of EFP (Cellulite)

NCT03632993
View directory record Official record
Conditions
Edematous Skin
Interventions
collagenase clostridium histolyticum (CCH)
Drug
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
5
States / cities
Coral Gables, Florida • Miami, Florida • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 7, 2023 · Synced Oct 9, 2026, 5:59 AM EDT